En
Non vérifié

Ensoma

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueSantéScience
10/12/2025
Industrie
Biologie
Biotechnologie
Santé Publique
Santé
Industrie pharmaceutique
Science
Médecine - Divers
Ensoma Announces Clearance of U.K. Clinical Trial Authorization Application for EN-374, First In Vivo HSC-Directed Gene Insertion Therapy
Source
1.00
01/12/2025
Science
Biotechnologie
Médecine - Divers
Biologie
Santé
Industrie pharmaceutique
Industrie
Ensoma Announces First Patient Dosed in Phase 1/2 Clinical Trial of EN-374 for Treatment of X-CGD
Source
1.00
04/11/2025
Science
Biotechnologie
Biologie
Santé
Industrie pharmaceutique
Santé Publique
Oncologie
Événements
Industrie
Ensoma Presents Preclinical Data Demonstrating Potential of In Vivo, HSC-derived CAR-M, NK, and T Platform for Solid Tumors at SITC 2025
Source
1.00
03/10/2025
Science
Biotechnologie
Santé
Industrie pharmaceutique
Santé Publique
Oncologie
Ensoma to Present New Preclinical Data at the Society for Immunotherapy of Cancer Annual Meeting
Source
1.00
12/05/2025
Industrie
Santé
Hygiène alimentaire
Biologie
Biotechnologie
Science
Industrie pharmaceutique
Ensoma Announces FDA Clearance of IND Application for First In Vivo HSC-Directed Gene Insertion Therapy
Source
1.00
29/04/2025
Événements
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé Publique
Santé
Ensoma to Present Preclinical Data and Manufacturing Advancements for In Vivo HSC Engineering Platform to Treat Cancer, Immune Disorders and Genetic Diseases at ASGCT 28th Annual Meeting
Source
1.00
13/02/2025
Science
VIH, SIDA et maladies auto-immunes
Hygiène alimentaire
Biotechnologie
Santé
Industrie pharmaceutique
Industrie
Ensoma Receives Rare Pediatric Disease and Orphan Drug Designations for EN-374 for Treatment of Chronic Granulomatous Disease
Source
1.00
05/11/2024
Événements
Biologie
Biotechnologie
Santé Publique
Santé
Industrie pharmaceutique
Oncologie
Science
Médecine - Divers
Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases
Source
1.00
28/10/2024
Marché du travail
Industrie
Biotechnologie
Hygiène alimentaire
Santé Publique
Santé
Industrie pharmaceutique
Oncologie
Science
Médecine - Divers
Ensoma Appoints Accomplished Deal Maker Jon Garen as Chief Corporate Development and Business Officer
Source
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0